Valuation: Moderna, Inc.

Capitalization 13.26B 11.34B 10.57B 9.77B 18.14B 1,137B 20.2B 126B 48.27B 531B 49.72B 48.7B 1,941B P/E ratio 2025 *
-3.39x
P/E ratio 2026 * -4.63x
Enterprise value 7.87B 6.73B 6.27B 5.8B 10.76B 674B 11.98B 74.98B 28.64B 315B 29.5B 28.89B 1,152B EV / Sales 2025 *
0.94x
EV / Sales 2026 * 4.32x
Free-Float
90.48%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.36%
1 week+12.43%
Current month+24.25%
1 month+23.84%
3 months+39.92%
6 months-18.86%
Current year-17.56%
More quotes
1 week 29.72
Extreme 29.72
34.39
1 month 25.06
Extreme 25.06
34.39
Current year 23.15
Extreme 23.15
48.92
1 year 23.15
Extreme 23.15
129.39
3 years 23.15
Extreme 23.15
217.25
5 years 23.15
Extreme 23.15
497.49
10 years 11.54
Extreme 11.54
497.49
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 2011-02-28
Director of Finance/CFO 48 2022-09-05
President 49 2024-10-31
Director TitleAgeSince
Director/Board Member 66 2018-05-31
Chairman 62 2012-01-31
Director/Board Member 52 2011-02-28
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+4.54%+12.43%-70.81%-80.55% 13.26B
-0.61%-0.03%-19.06%-16.34% 77.04B
+1.30%+2.27%-47.74%-9.94% 59.15B
+6.09%+8.00%+35.68%+31.87% 55.99B
+1.35%+3.54%+19.90%+100.84% 38.34B
+1.74%+1.85%-41.86%-38.15% 19.83B
+6.02%+14.39%+71.05%+743.19% 17.48B
+1.31%-4.26%+124.38%+122.22% 17.48B
-0.04%-.--%+70.62%+129.06% 14.02B
+2.36%+2.76%+15.82%-12.60% 13.62B
Average +1.95%+4.00%+15.80%+96.96% 32.62B
Weighted average by Cap. +1.89%+3.07%+4.05%+57.46%
See all sector performances

Financials

2025 *2026 *
Net sales 2.07B 1.77B 1.65B 1.53B 2.83B 178B 3.15B 19.74B 7.54B 82.95B 7.76B 7.6B 303B 2.4B 2.05B 1.91B 1.77B 3.28B 206B 3.66B 22.88B 8.74B 96.17B 9B 8.82B 351B
Net income 1.33B 1.14B 1.06B 980M 1.82B 114B 2.02B 12.67B 4.84B 53.23B 4.98B 4.88B 195B 1.92B 1.64B 1.53B 1.41B 2.62B 164B 2.92B 18.26B 6.97B 76.75B 7.18B 7.04B 281B
Net Debt -5.39B -4.61B -4.3B -3.98B -7.38B -462B -8.22B -51.4B -19.63B -216B -20.22B -19.81B -790B -2.88B -2.46B -2.29B -2.12B -3.94B -247B -4.38B -27.42B -10.47B -115B -10.79B -10.57B -421B
More financial data * Estimated data
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).
Employees
5,800
More about the company
Date Price Change Volume
25-07-10 34.28 $ +4.54% 11,693,076
25-07-09 32.79 $ +0.77% 9,819,691
25-07-08 32.54 $ +8.83% 19,295,041
25-07-07 29.90 $ -1.94% 8,221,852
25-07-03 30.49 $ +0.69% 6,972,646

Delayed Quote Nasdaq, July 10, 2025 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
34.28USD
Average target price
47.59USD
Spread / Average Target
+38.83%
Consensus

Quarterly revenue - Rate of surprise